Interleukin-6 receptor and its ligand interleukin-6 are opposite markers for survival and infiltration with mature myeloid cells in ovarian cancer

por Wouters, MCA, Dijkgraaf, EM, Kuijjer, ML, Jordanova, ES, Hollema, H, Welters, MJP, van der Hoeven, JJM, Daemen, T, Kroep, JR, Nijman, HW, van der Burg, SH
Publicado 2015

601TiP First-in-human phase I study of a novel oral Wee1 inhibitor (Debio 0123) in combination with carboplatin in patients with advanced solid tumours

por Gelderblom, H., Gietema, J.A., Desar, I.M.E., Ajmone, N.M., Jalving, M., Kroep, J.R., Nicolas, V., Vaslin, A., Tobal, K., Purcea, D., van Haren, S.F., Damstrup, L.
Publicado 2020

Effects of neoadjuvant chemotherapy with or without zoledronic acid on pathological response: A meta-analysis of randomised trials

por Kroep, J.R., Charehbili, A., Coleman, R.E., Aft, R.L., Hasegawa, Y., Winter, M.C., Weilbaecher, K., Akazawa, K., Hinsley, S., Putter, H., Liefers, G.J., Nortier, J.W.R., Kohno, N.
Publicado 2015